COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features

Angelo Antonini, Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, Marco Onofrj, Mario Zappia, Aldo Quattrone

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Levodopa is the most effective treatment in Parkinson's disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce "off" time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalNeuropsychiatric Disease and Treatment
Volume4
Issue number1 A
Publication statusPublished - 2008

Fingerprint

Parkinson Disease
Levodopa
Therapeutics
Monoamine Oxidase Inhibitors
Liver
Monoamine Oxidase
Biological Availability
tolcapone
Guidelines
Safety

Keywords

  • COMT inhibitors
  • Levodopa
  • Motor fluctuations
  • Parkinson's disease
  • Tolcapone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Antonini, A., Abbruzzese, G., Barone, P., Bonuccelli, U., Lopiano, L., Onofrj, M., ... Quattrone, A. (2008). COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features. Neuropsychiatric Disease and Treatment, 4(1 A), 1-9.

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD) : Relevance for motor and non-motor features. / Antonini, Angelo; Abbruzzese, Giovanni; Barone, Paolo; Bonuccelli, Ubaldo; Lopiano, Leonardo; Onofrj, Marco; Zappia, Mario; Quattrone, Aldo.

In: Neuropsychiatric Disease and Treatment, Vol. 4, No. 1 A, 2008, p. 1-9.

Research output: Contribution to journalArticle

Antonini, A, Abbruzzese, G, Barone, P, Bonuccelli, U, Lopiano, L, Onofrj, M, Zappia, M & Quattrone, A 2008, 'COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features', Neuropsychiatric Disease and Treatment, vol. 4, no. 1 A, pp. 1-9.
Antonini, Angelo ; Abbruzzese, Giovanni ; Barone, Paolo ; Bonuccelli, Ubaldo ; Lopiano, Leonardo ; Onofrj, Marco ; Zappia, Mario ; Quattrone, Aldo. / COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD) : Relevance for motor and non-motor features. In: Neuropsychiatric Disease and Treatment. 2008 ; Vol. 4, No. 1 A. pp. 1-9.
@article{22c04ecdf858473a98f2212e183f5ee6,
title = "COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): Relevance for motor and non-motor features",
abstract = "Levodopa is the most effective treatment in Parkinson's disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce {"}off{"} time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.",
keywords = "COMT inhibitors, Levodopa, Motor fluctuations, Parkinson's disease, Tolcapone",
author = "Angelo Antonini and Giovanni Abbruzzese and Paolo Barone and Ubaldo Bonuccelli and Leonardo Lopiano and Marco Onofrj and Mario Zappia and Aldo Quattrone",
year = "2008",
language = "English",
volume = "4",
pages = "1--9",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "1 A",

}

TY - JOUR

T1 - COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD)

T2 - Relevance for motor and non-motor features

AU - Antonini, Angelo

AU - Abbruzzese, Giovanni

AU - Barone, Paolo

AU - Bonuccelli, Ubaldo

AU - Lopiano, Leonardo

AU - Onofrj, Marco

AU - Zappia, Mario

AU - Quattrone, Aldo

PY - 2008

Y1 - 2008

N2 - Levodopa is the most effective treatment in Parkinson's disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce "off" time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.

AB - Levodopa is the most effective treatment in Parkinson's disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce "off" time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied.

KW - COMT inhibitors

KW - Levodopa

KW - Motor fluctuations

KW - Parkinson's disease

KW - Tolcapone

UR - http://www.scopus.com/inward/record.url?scp=41549148649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549148649&partnerID=8YFLogxK

M3 - Article

C2 - 18728767

AN - SCOPUS:41549148649

VL - 4

SP - 1

EP - 9

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 1 A

ER -